Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

Abstract Background Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2. The STRATOS 1 biomarker analysis plan was developed to identify biomarker(s) indicative of IL-13 activa...

Full description

Bibliographic Details
Main Authors: Mattis Gottlow, David J. Svensson, Ilya Lipkovich, Monika Huhn, Karin Bowen, Peter Wessman, Gene Colice
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Pulmonary Medicine
Subjects:
Asthma
IL-13
Predictive biomarker
SIDES (subgroup identification based on differential effect search)
STRATOS 1
STRATOS 2
Online Access:http://link.springer.com/article/10.1186/s12890-019-0889-4

Internet

http://link.springer.com/article/10.1186/s12890-019-0889-4

Similar Items